Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailendra Verma

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOXavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancerHope S Rugo, Alison T Stopeck, Anil A Joy, et al.
Clinical Breast Cancer|May 14, 2004
Use of trastuzumab beyond disease progression: observations from a retrospective review of case historiesKaren A Gelmon, John Mackey, Shailendra Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJoyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2018
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)Mark Clemons, Sasha Mazzarello, John Hilton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of responseNan Soon Wong, Robert A Buckman, Mark Clemons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOXavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancerHope S Rugo, Alison T Stopeck, Anil A Joy, et al.
Clinical Breast Cancer|May 14, 2004
Use of trastuzumab beyond disease progression: observations from a retrospective review of case historiesKaren A Gelmon, John Mackey, Shailendra Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJoyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2018
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)Mark Clemons, Sasha Mazzarello, John Hilton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of responseNan Soon Wong, Robert A Buckman, Mark Clemons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.
Pageof 6